Catalogo dei prodotti della ricerca

SERRAO, ALESSANDRA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.637
AS - Asia 1.077
EU - Europa 734
SA - Sud America 202
AF - Africa 51
OC - Oceania 3
Continente sconosciuto - Info sul continente non disponibili 1
Totale 4.705
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.605
SG - Singapore 493
IT - Italia 202
BR - Brasile 167
HK - Hong Kong 153
CN - Cina 143
IN - India 128
DE - Germania 116
SE - Svezia 110
FI - Finlandia 69
VN - Vietnam 60
RU - Federazione Russa 48
BG - Bulgaria 36
UA - Ucraina 28
GB - Regno Unito 26
JP - Giappone 25
RO - Romania 22
TG - Togo 17
AR - Argentina 15
CA - Canada 15
ID - Indonesia 15
AT - Austria 11
BD - Bangladesh 10
FR - Francia 10
IQ - Iraq 10
BE - Belgio 9
IE - Irlanda 9
MX - Messico 9
CH - Svizzera 8
MA - Marocco 7
NL - Olanda 7
PK - Pakistan 6
SA - Arabia Saudita 6
VE - Venezuela 6
TR - Turchia 5
CI - Costa d'Avorio 4
ET - Etiopia 4
PL - Polonia 4
ZA - Sudafrica 4
CO - Colombia 3
CZ - Repubblica Ceca 3
EC - Ecuador 3
KE - Kenya 3
LV - Lettonia 3
NG - Nigeria 3
UZ - Uzbekistan 3
AL - Albania 2
AO - Angola 2
AU - Australia 2
AZ - Azerbaigian 2
DK - Danimarca 2
ES - Italia 2
JO - Giordania 2
KZ - Kazakistan 2
OM - Oman 2
PA - Panama 2
PE - Perù 2
PH - Filippine 2
PR - Porto Rico 2
PY - Paraguay 2
SK - Slovacchia (Repubblica Slovacca) 2
TW - Taiwan 2
UY - Uruguay 2
AE - Emirati Arabi Uniti 1
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BJ - Benin 1
BN - Brunei Darussalam 1
BO - Bolivia 1
CL - Cile 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
EG - Egitto 1
HN - Honduras 1
HU - Ungheria 1
IS - Islanda 1
JM - Giamaica 1
KG - Kirghizistan 1
KR - Corea 1
LT - Lituania 1
MG - Madagascar 1
MY - Malesia 1
NP - Nepal 1
NZ - Nuova Zelanda 1
PS - Palestinian Territory 1
RS - Serbia 1
SC - Seychelles 1
SN - Senegal 1
TN - Tunisia 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 4.705
Salva come PNG Salva come JPEG
Città #
Fairfield 393
Ashburn 286
Singapore 286
Seattle 175
Woodbridge 173
Houston 166
Hong Kong 148
Chandler 147
Cambridge 133
Wilmington 126
Santa Clara 82
Ann Arbor 71
San Paolo di Civitate 56
Dallas 54
Princeton 52
Hillsboro 51
Los Angeles 51
Rome 48
Millbury 47
Munich 40
Lawrence 38
Beijing 37
Sofia 36
Frankfurt am Main 32
San Diego 30
Buffalo 29
Plano 28
Bremen 25
Cosenza 23
Helsinki 19
Ho Chi Minh City 19
Tokyo 18
Turku 18
Bengaluru 17
Hanoi 17
Lomé 17
Andover 16
New York 16
Redondo Beach 16
São Paulo 15
Bologna 14
Boston 14
Moscow 14
Trento 12
Council Bluffs 9
Dublin 9
London 9
Norwalk 9
Nuremberg 9
Brussels 8
Jakarta 8
Toronto 8
Boardman 6
Jacksonville 6
Bern 5
Chicago 5
Des Moines 5
Lappeenranta 5
Mexico City 5
Ottawa 5
Shanghai 5
Vienna 5
Abidjan 4
Addis Ababa 4
Casablanca 4
Columbus 4
Dearborn 4
Milan 4
Phoenix 4
Riyadh 4
Salvador 4
Yubileyny 4
Atlanta 3
Baghdad 3
Bari 3
Belo Horizonte 3
Brasília 3
Brooklyn 3
Campinas 3
Clementon 3
Curitiba 3
Da Nang 3
Falkenstein 3
Guangzhou 3
Kunming 3
Nairobi 3
Pune 3
Queens 3
Redwood City 3
Riga 3
Salt Lake City 3
Tashkent 3
Thái Bình 3
Agadir 2
Albino 2
Almaty 2
Amman 2
Araxá 2
Araçariguama 2
Auburn Hills 2
Totale 3.343
Salva come PNG Salva come JPEG
Nome #
5-Azacitidine efficacy and safety in patients aged >65 years with myelodysplastic syndromes outside clinical trials. 148
Azacitidine Followed by Radiotherapy as Effective Treatment for Chronic Myelomonocytic Leukemia with Extramedullary Localization. 136
Thrombopoietin receptor agonists to control immune thrombocytopenia in patients with active lymphoma 134
Current and future therapeutic approaches for the treatment of follicular lymphoma 128
Isolated central nervous system relapse after nine years of complete molecular remission in a lymphoid blast crisis of chronic myeloid leukemia treated with imatinib. 124
. BEAM vs FEAM conditioning: retrospective study in lymphoma patients undergoing autologous stem cell transplant. 122
MDS-specific comorbidity index is useful to identify myelodysplastic patients who can have better outcome with 5-azacitidine 115
Combination of azacitidine and ESA in myelodysplastic patients: The need for prospective studies 111
Antithrombin concentrate during pregnancy in congenital antithrombin deficiency: A single-center experience 109
Direct oral anticoagulants in patients affected by major congenital thrombophilia 106
Long-term response to daratumumab in a patient with advanced immunoglobulin light-chain (AL) amyloidosis with organ damage 106
Concomitant Administration of Direct Oral Anticoagulants in Chronic Phase Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors 105
Application of French prognostic score to patients with International Prognostic Scoring System intermediate-2 or high risk myelodysplastic syndromes treated with 5-azacitidine is able to predict overall survival and rate of response 102
Nivolumab as a safe and effective treatment in an HIV patient with refractory Hodgkin lymphoma 100
Use of edoxaban for the treatment of venous thromboembolism in HIV-infected patients 98
The degree of anemia has an impact on survival in myelodysplastic syndrome patients classified with WPSS. 98
Dasatinib combined with weekly administration of vincristine as effective therapy in sudden or resistant Ph+ lymphoid blast crisis of chronic myeloid leukaemia. 98
Response to interferon-free direct antivirals (DAAS) treatment in Hcv-related subcutaneous marginal zone B-cell lymphoma with lipoma-like presentation: report of two cases 97
Deferasirox treatment for myelodysplastic syndromes: "real-life" efficacy and safety in a single-institution patient population. 97
Azacitidine as salvage therapy in elderly patients with relapsed acute myeloid leukemia after autologous transplantation. 96
Adaptive evolution of male accessory gland proteins involved in post-mating reproductive mechanisms of the african malaria mosquito Anopheles gambiae. 95
Disappearance of fibrosis in secondary myelofibrosis after ruxolitinib treatment: new endpoint to achieve? 93
Low incidence rate of opportunistic and viral infections during imatinib treatment in chronic myeloid leukemia patients in early and late chronic phase. 93
Application of comorbidity indexes at baseline could be useful to predict rates of response in patients with chronic myeloid leukemia treated with imatinib. 92
Fasting glucose level reduction induced by imatinib in chronic myeloproliferative disease with TEL-PDGFRβ rearrangement and type 1 diabetes. 91
Venous thromboembolism prophylaxis in patients with multiple myeloma: where are we and where are we going? 91
Evaluation of overall survival according to myelodysplastic syndrome-specific comorbidity index in a large series of myelodysplastic syndromes. 89
Evaluation of prognostic factors for overall survival in patients with chronic myelomonocytic leukemia by different scoring systems: which is the best? 88
PICC-related upper deep venous thrombosis in patients with hematological malignancies. Management of anticoagulant therapy according to the platelet count 85
A Multicenter Real-Life Study On Anticoagulant Treatment With Direct Oral Anticoagulants In Patients With Ph Negative Myeloproliferative Neoplasms 85
Single centre experience on Acquired Haemophilia A patients: Diagnosis, clinical management and analysis of factors predictive of response and outcome 85
Direct oral anticoagulants for the treatment of Mondor's disease not responding to low-molecular weight heparin 84
Delayed cytogenetic and major molecular responses associated to increased BMI at baseline in chronic myeloid leukemia patients treated with imatinib. 83
Nilotinib-mediated increase in fasting glucose level is reversible, does not convert to type 2 diabetes and is likely correlated with increased body mass index. 80
Direct Oral Anticoagulants In Patients With Hematologic Malignancies 79
Nilotinib therapy does not induce consistent modifications of cholesterol metabolism resulting in clinical consequences. 79
Satisfaction, quality of life and therapy adherence assessment in real life patients transitioning from vitamin K antagonists to direct oral anticoagulants 78
Cancer-associated venous thromboembolism: the Onco-VTE START2 - Registry 76
Isodicentric duplication of Philadelphia chromosome as a mechanism of resistance to dasatinib in a patient with chronic myeloid leukemia after resistance to imatinib 75
Neutropenia at baseline could indicate poor prognosis in low/intermediate risk myelodysplastic syndrome patients 74
Outcomes of long‐term anticoagulant treatment for the secondary prophylaxis of splanchnic venous thrombosis 69
The treatment of upper extremities deep vein thrombosis related to thoracic outlet syndrome with direct oral anticoagulants 68
post filter thromboembolic prophylaxis in vena cava filter carriers 67
Role of Factor V R2 Haplotype and Common Thrombophilia Markers as Genetic Risk Factors for Ischemic Stroke 67
Secondary prophylaxis of venous thromboembolism with direct oral anticoagulants (DOACs) in patients with major congenital thrombophilia 66
Imatinib induces body mass changes in women with chronic myeloid leukemia. 61
The EUTOS score identifies chronic myeloid leukeamia patients with poor prognosis treated with imatinib first or second line. 61
Trisomy 8 in Philadelphia chromosome negative cell preceding the evolution of a Philadelphia chromosome positive clone with the same additional change during imatinib treatment: revisiting the role of genetic instability in chronic myeloid leukemia 61
Hemorrhagic Complications in Patients Treated With Azacitidine and Direct Oral Anticoagulants 61
MDS-Specific Comorbidity Index (MDS-CI) Identifies Overall Survival Differences in Myelodysplastic Syndrome Patients. 60
Secondary prophylaxis of venous thromboembolism with direct oral anticoagulants: comparison between patients with major congenital thrombophilia versus non-thrombophilic patients 56
Thromboembolic events following mRNA vaccines for COVID 19: a case series 52
Secondary Prophylaxis of Venous Thromboembolism (VTE) with Low Dose Apixaban or Rivaroxaban: Results from a Patient Population with More than 2 Years of Median Follow-up 51
D-dimer and reduced-dose apixaban for extended treatment after unprovoked venous thromboembolism. the apidulcis study 50
Prognostic Features of Myelodysplastic Syndrome Patients Aged < 50 years: Update of a Single Institution Experience. 47
Real-world use of direct oral anticoagulants in atrial fibrillation patients with moderate/severe chronic kidney disease: a propensity score matched analysis from the START registry 5
Totale 4.827
Salva come PNG Salva come JPEG
Categoria #
all - tutte 14.540
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 14.540
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021307 0 0 0 0 25 91 39 36 32 31 32 21
2021/2022569 20 28 59 4 58 29 13 48 42 48 117 103
2022/2023638 100 143 42 61 55 77 17 37 75 3 22 6
2023/2024256 14 42 4 10 17 69 3 12 3 41 20 21
2024/20251.075 20 66 29 39 83 44 64 47 193 99 60 331
2025/2026884 243 90 230 155 166 0 0 0 0 0 0 0
Totale 4.827